Third Harmonic Bio Revenue and Competitors
Estimated Revenue & Valuation
- Third Harmonic Bio's estimated annual revenue is currently $2.6M per year.
- Third Harmonic Bio's estimated revenue per employee is $77,500
Employee Data
- Third Harmonic Bio has 34 Employees.
- Third Harmonic Bio grew their employee count by 42% last year.
Third Harmonic Bio's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Executive Assistant || CEO & CFO | Reveal Email/Phone |
3 | Chief Financial and Business Officer | Reveal Email/Phone |
4 | Chief Administrative Officer | Reveal Email/Phone |
5 | Chief Development Operations Officer | Reveal Email/Phone |
6 | COO | Reveal Email/Phone |
7 | Chief Financial Officer | Reveal Email/Phone |
8 | Executive Assistant & Office Operations Manager || CAO & CMO | Reveal Email/Phone |
9 | Chief Medical Officer | Reveal Email/Phone |
10 | SVP Drug Discovery and Product Development | Reveal Email/Phone |
Third Harmonic Bio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Third Harmonic Bio?
Third Harmonic Bio is a clinical-stage company developing a highly selective, oral KIT inhibitor for treatment of severe allergy and inflammation. KIT is a cell surface receptor that acts as the master survival and functional regulator of mast cells, which are immune cells concentrated at the body’s interfaces with the external environment and that act as the key mediator of the inflammation associated with allergic diseases. Our lead product candidate, THB001, is the first highly selective, oral small-molecule KIT inhibitor to enter clinical development. With promising drug-like properties and an encouraging early clinical profile, THB001 has the potential to revolutionize the treatment of a broad range of dermatologic, respiratory, and gastrointestinal allergic and mast-cell mediated inflammatory diseases.
keywords:N/A
N/A
Total Funding
34
Number of Employees
$2.6M
Revenue (est)
42%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $8.5M | 34 | 6% | N/A |
#2 | $6M | 34 | -11% | N/A |
#3 | $5.7M | 34 | -6% | N/A |
#4 | $4.1M | 34 | 3% | N/A |
#5 | $35M | 34 | -6% | N/A |